Mohamad A. Mikati

Mohamad A. Mikati

Auto-generated profile, based on publicly available information

Mohamad A. Mikati

Division of Pediatric Neurology and Developmental Medicine, Department of Pediatrics, Duke University, Durham, North Carolina, USA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
EHErin L Heinzen
Erin L Heinzen
KSKathryn J Swoboda
Kathryn J Swoboda
YHYuki Hitomi
Yuki Hitomi
FIORELLA GURRIERIFIORELLA GURRIERI
FIORELLA GURRIERI
SNSophie Nicole
Sophie Nicole
DGDavid B Goldstein
David B Goldstein
David Goldstein, Mohamad Mikati and colleagues report identification of de novo mutations in ATP1A3 in alternating hemiplegia of childhood, which is a rare neurodevelopmental syndrome characterized by recurrent hemiplegic episodes and distinct neurologic manifestations. Alternating hemiplegia of childhood (AHC) is a rare, severe neurodevelopmental syndrome characterized by recurrent hemiplegic episodes and distinct neurological manifestations. AHC is usually a sporadic disorder and has unknown etiology. We used exome sequencing of seven patients with AHC and their unaffected parents to identify de novo nonsynonymous mutations in ATP1A3 in all seven individuals. In a subsequent sequence analysis of ATP1A3 in 98 other patients with AHC, we found that ATP1A3 mutations were likely to be responsible for at least 74% of the cases; we also identified one inherited mutation in a case of familial AHC. Notably, most AHC cases are caused by one of seven recurrent ATP1A3 mutations, one of which was observed in 36 patients. Unlike ATP1A3 mutations that cause rapid-onset dystonia-parkinsonism, AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression. This work identifies de novo ATP1A3 mutations as the primary cause of AHC and offers insight into disease pathophysiology by expanding the spectrum of phenotypes associated with mutations in ATP1A3.

14 May 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
GFG. Farhat
G. Farhat
BYB. Yamout
B. Yamout
MMM. A. Mikati
M. A. Mikati
SDS. Demirjian
S. Demirjian
RSR. Sawaya
R. Sawaya
GFG. El-Hajj Fuleihan
G. El-Hajj Fuleihan
Background: Long-term antiepileptic drug (AED) use causes multiple abnormalities in calcium and bone metabolism that have been most extensively described in institutionalized patients. The objective is to determine the effect of AED on vitamin D levels and bone density in ambulatory patients and to compare the effects of enzyme-inducing and -noninducing AED and of single vs multiple therapy on bone density. Methods: A cross-sectional evaluation was conducted of 71 patients (42 adults and 29 children/adolescents) on anticonvulsant therapy for at least 6 months who presented to neurologists at a tertiary referral center. Bone mineral density (BMD) as well as serum 25 hydroxy–vitamin D (25-OHD) levels were measured. A detailed questionnaire assessing calcium intake as well as previous and current intake of antiepileptic medications was administered to all patients. Results: Over 50% of adults and children/adolescents had low 25-OHD levels, but this finding did not correlate with BMD. Antiepileptic therapy decreased BMD in adults. Generalized seizures, duration of epilepsy, and polypharmacy were significant determinants of BMD, more so at skeletal sites enriched in cortical bone. Subjects on enzyme-inducing drugs such as phenytoin, phenobarbital, carbamazepine, and primidone tended to have lower BMD than those on noninducers such as valproic acid, lamotrigine, clonazepam, gabapentin, topamirate, and ethosuximide. Conclusion: Epilepsy and its therapy, including the newer drugs, are risk factors for low bone density, irrespective of vitamin D levels. Skeletal monitoring with the institution of appropriate therapy is indicated in patients on chronic antiepileptic therapy.

1 May 2010 in The American Journal of Human Genetics
Verified
Journal Article
Open access
EHErin L. Heinzen
Erin L. Heinzen
RRRodney A. Radtke
Rodney A. Radtke
TUThomas J. Urban
Thomas J. Urban
GCGianpiero L. Cavalleri
Gianpiero L. Cavalleri
CDChantal Depondt
Chantal Depondt
DGDavid B. Goldstein
David B. Goldstein
Deletions at 16p13.11 are associated with schizophrenia, mental retardation, and most recently idiopathic generalized epilepsy. To evaluate the role of 16p13.11 deletions, as well as other structural variation, in epilepsy disorders, we used genome-wide screens to identify copy number variation in 3812 patients with a diverse spectrum of epilepsy syndromes and in 1299 neurologically-normal controls. Large deletions (> 100 kb) at 16p13.11 were observed in 23 patients, whereas no control had a deletion greater than 16 kb. Patients, even those with identically sized 16p13.11 deletions, presented with highly variable epilepsy phenotypes. For a subset of patients with a 16p13.11 deletion, we show a consistent reduction of expression for included genes, suggesting that haploinsufficiency might contribute to pathogenicity. We also investigated another possible mechanism of pathogenicity by using hybridization-based capture and next-generation sequencing of the homologous chromosome for ten 16p13.11-deletion patients to look for unmasked recessive mutations. Follow-up genotyping of suggestive polymorphisms failed to identify any convincing recessive-acting mutations in the homologous interval corresponding to the deletion. The observation that two of the 16p13.11 deletions were larger than 2 Mb in size led us to screen for other large deletions. We found 12 additional genomic regions harboring deletions > 2 Mb in epilepsy patients, and none in controls. Additional evaluation is needed to characterize the role of these exceedingly large, non-locus-specific deletions in epilepsy. Collectively, these data implicate 16p13.11 and possibly other large deletions as risk factors for a wide range of epilepsy disorders, and they appear to point toward haploinsufficiency as a contributor to the pathogenicity of deletions.

1 May 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
EHErin L Heinzen
Erin L Heinzen
AAAlexis Arzimanoglou
Alexis Arzimanoglou
ABAllison Brashear
Allison Brashear
SCSteven J Clapcote
Steven J Clapcote
FIORELLA GURRIERIFIORELLA GURRIERI
FIORELLA GURRIERI
BVBente Vilsen
Bente Vilsen

15 September 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MMMohamad A Mikati
Mohamad A Mikati
YJYong‐Hui Jiang
Yong‐Hui Jiang
MCMichael Carboni
Michael Carboni
VSVandana Shashi
Vandana Shashi
SPSlave Petrovski
Slave Petrovski
DGDavid Goldstein
David Goldstein

1 August 2000 in Pediatric Neurology
Verified
Journal Article
Closed access
MMMohamad A Mikati
Mohamad A Mikati
UKUri Kramer
Uri Kramer
MZMary L Zupanc
Mary L Zupanc
RSRobin J Shanahan
Robin J Shanahan